5,7-二氯吡唑并[1,5-A]嘧啶 | 57489-77-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 5,7-二氯吡唑并[1,5-A]嘧啶
• 中文别名: 5,7-二氯吡唑并[1,5-a]嘧啶；5,7二氯嘧啶并吡唑
• 英文名称: 5,7-dichloropyrazolo[1,5-a]pyrimidine
• 英文别名: 5,7-dichloropyrazolo<1,5-a>pyrimidine
• CAS: 57489-77-7
• 化学式: C₆H₃Cl₂N₃
• 分子量: 188.016
• InChiKey: JMTFWCYVZOFHLR-UHFFFAOYSA-N

物化性质

• 熔点：
  68-71 °C(Solv: ethanol (64-17-5))
• 密度：
  1.69±0.1 g/cm3(Predicted)
• pKa：
  -1.68±0.30 (Predicted,Most Basic Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5,7-Dichloropyrazolo[1,5-a]pyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5,7-Dichloropyrazolo[1,5-a]pyrimidine
CAS number: 57489-77-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3Cl2N3
Molecular weight: 188.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

5,7-二氯吡唑并[1,5-A]嘧啶在常温常压下为白色固体，与吡啶相似，嘧啶部分保留了芳香性。这种化合物主要用作医药中间体和感光剂的原料。

用途

5,7-二氯吡唑并[1,5-A]嘧啶可用作医药中间体及感光剂的原料。由于受嘧啶缺电子的影响，该化合物中的氯原子容易被亲核试剂进攻，从而得到脱氯官能团化的产物。此外，还可以利用N-氯代丁二酰亚胺在吡唑环上引入一个氯原子。

制备方法

制备5,7-二氯吡唑并[1,5-A]嘧啶的具体步骤如下：首先，在冰水浴中，将真空干燥后的反应瓶加入1克（6.62毫摩尔）的吡唑并[1,5-a]嘧啶-5,7(4H,6H)-二酮、7.5毫升（82毫摩尔）三氯氧膦和1.2毫升（9.5毫摩尔）N,N-二甲基苯胺。随后，将反应混合物加热至回流状态并反应4小时。待反应完成后，将混合物倒入50mL冰水中，用乙酸乙酯萃取三次，合并提取出的有机层，并使用盐水洗涤。然后用无水硫酸钠干燥有机层，过滤除去硫酸钠固体，最后在真空条件下蒸发溶剂即可得到目标产物——5,7-二氯吡唑并[1,5-A]嘧啶。

图 5,7-二氯吡唑并[1,5-A]嘧啶的合成路线

反应信息

• 作为反应物：
  描述：

  5,7-二氯吡唑并[1,5-A]嘧啶 在 溶剂黄146 potassium carbonate 、 一水合肼 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 1.75h， 生成 N-(1H-indol-3-yl-methylidene)-N'-(7-morpholin-4-yl-pyrazolo[1,5-a]pyrimidin-5-yl)-hydrazine
  参考文献：
  名称：

  PYRAZOLO-PYRIMIDINE COMPOUNDS

  摘要：

  本发明已经寻找到多种显示IL-12/IL-23产生抑制活性的化合物，并在此提供了包括该化合物的用于预防或治疗IL-12/IL-23过度产生相关疾病的药物组合物和药剂。

  公开号：

  US20110294781A1
• 作为产物：
  描述：

  4,5-dihydropyrazolo[1,5-a]pyrimidine-5,7-diol 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 12.0h， 以77%的产率得到5,7-二氯吡唑并[1,5-A]嘧啶
  参考文献：
  名称：

  유기 화합물 및 이를 포함하는 유기 전계 발광 소자

  摘要：

  该发明涉及一种有优异发光性能的新型化合物及其通过将其包含在一个或多个有机层中来提高有机电致发光器件的发光效率、驱动电压、寿命等特性。

  公开号：

  KR20160095474A

文献信息

• [EN] PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS<br/>[FR] PYRAZOLOPYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES DEPENDANTES DES CYCLINES
  申请人：SCHERING CORP

  公开号：WO2004022062A1

  公开（公告）日：2004-03-18

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一类新型的吡唑并[1,5-a]嘧啶化合物，作为细胞周期依赖性激酶的抑制剂，以及制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及利用这类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
• [EN] PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS<br/>[FR] PYRAZOLOPYRIMIDINES TENANT LIEU D'INHIBITEURS DE KINASES DEPENDANTES DE LA CYCLINE
  申请人：SCHERING CORP

  公开号：WO2004022561A1

  公开（公告）日：2004-03-18

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一类新型的吡唑并[1,5-a]嘧啶化合物，作为细胞周期依赖性激酶的抑制剂，以及制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及利用这类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。
• Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAP-K2) as an Antiinflammatory Target: Discovery and in Vivo Activity of Selective Pyrazolo[1,5-<i>a</i>]pyrimidine Inhibitors Using a Focused Library and Structure-Based Optimization Approach
  作者：Tomomi Kosugi、Dale R. Mitchell、Aiko Fujino、Minoru Imai、Mika Kambe、Shinji Kobayashi、Hiroaki Makino、Yohei Matsueda、Yasuhiro Oue、Kanji Komatsu、Keiichiro Imaizumi、Yuri Sakai、Satoshi Sugiura、Osami Takenouchi、Gen Unoki、Yuko Yamakoshi、Vicky Cunliffe、Julie Frearson、Richard Gordon、C. John Harris、Heidi Kalloo-Hosein、Joelle Le、Gita Patel、Donald J. Simpson、Brad Sherborne、Peter S. Thomas、Naotaka Suzuki、Midori Takimoto-Kamimura、Ken-ichiro Kataoka

  DOI：10.1021/jm300411k

  日期：2012.8.9

  A novel class of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) inhibitors was discovered through screening a kinase-focused library. A homology model of MAPKAP-K2 was generated and used to guide the initial SAR studies and to rationalize the observed selectivity over CDK2. An X-ray crystal structure of a compound from the active series bound to crystalline MAPKAP-K2 confirmed

  通过筛选激酶集中的文库，发现了一类新型的促分裂原活化蛋白激酶活化蛋白激酶2（MAPKAP-K2）抑制剂。MAPKAP-K2的同源性模型已生成，可用于指导最初的SAR研究并合理化所观察到的对CDK2的选择性。结合到晶体MAPKAP-K2的活性系列化合物的X射线晶体结构证实了预测的结合模式。这使得能够发现一系列吡唑并[1,5- a ]嘧啶衍生物，它们在抗内毒素休克的小鼠模型中作为抗TNF-α剂具有良好的体外细胞效价和体内功效。
• [EN] BIARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS BIARYLES DE KINASES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017059080A1

  公开（公告）日：2017-04-06

  The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

  本公开涉及公式（I）的联苯化合物，可以抑制AAK1（适配器相关激酶1），包括这种化合物的组合物以及它们用于治疗疼痛、阿尔茨海默病、帕金森病和精神分裂症等的用途。
• [EN] PIKFYVE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE PIKFYVE
  申请人：ACURASTEM INCORPORATED

  公开号：WO2021163727A1

  公开（公告）日：2021-08-19

  The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

  本发明涉及作为磷脂酰肌醇-3-磷酸5-激酶（PIKfyve）抑制剂的化合物，以及它们用于治疗与PIKfyve相关的疾病和紊乱的用途。